Oxadiazolyl thiazolidinedione as a non-adipogenic PPAR- γ partial agonist and its effect on glucose homeostasis in type 2 diabetes.
In conclusion, OXTZD could be developed as a therapeutic agent for diabetes and/or serve as a lead compound for further drug design studies targeting PPAR-γ for effective management of type 2 diabetes without inducing weight gain.
PMID: 31204468 [PubMed - in process]
Source: Journal of Biological Regulators and Homeostatic Agents - Category: Biomedical Science Tags: J Biol Regul Homeost Agents Source Type: research
More News: Avandia | Biomedical Science | Diabetes | Diabetes Type 2 | Endocrinology | Insulin | Molecular Biology | Study